Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro.
1: Non-dopamine (putative GABAergic) neurons in the ventral tegmental area are in a position to influence mesolimbic functions by their inhibitory terminals that impinge locally on dopamine neurons and via their GABAergic efferents that innervate mesolimbic structures. In the present study we investigated responses of non-dopamine and dopamine neurons, recorded intracellularly in the rat midbrain slice, to orphanin FQ/nociceptin, the endogenous ligand for opioid receptor-like orphan receptors. 2: When recording in either non-dopamine or dopamine neurons, orphanin FQ/nociceptin reduced the frequency of spike firing and caused membrane hyperpolarization under current-clamp, or produced outward current under voltage-clamp. Such responses were concentration-dependent and reversed at -108 mV and -102 mV in non-dopamine and dopamine neurons, respectively. 3: Hyperpolarizations to orphanin FQ/nociceptin were not altered by tetrodotoxin or the opioid receptor antagonist naloxone, but were reduced by the opioid receptor-like orphan receptor antagonist [Phe1(1)phiCH(2)-NH)Gly(2)]NC(1-13)NH(2) (1 microM). 4: In dopamine neurons, orphanin FQ/nociceptin reduced the frequency of bicuculline- and tetrodotoxin-sensitive spontaneous inhibitory postsynaptic potentials, and reduced the amplitude of stimulus-evoked inhibitory postsynaptic potentials. 5: Taken together, the above data provide evidence that both non-dopamine and dopamine neurons are important substrates for orphanin FQ/nociceptin within the ventral tegmental area. Simultaneous inhibition of both non-dopamine and dopamine pathways by orphanin FQ/nociceptin may account for its influences on various ventral tegmental area-related functions.
Zheng
Fang
F
Department of Physiology and Pharmacology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, U.S.A.
Grandy
David K
DK
Johnson
Steven W
SW
D000704:Analysis of Variance; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D005071:Evoked Potentials; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D018847:Opioid Peptides / Q000378:metabolism / Q000494:pharmacology*; D018408:Patch-Clamp Techniques; D051381:Rats; D017207:Rats, Sprague-Dawley; D009435:Synaptic Transmission; D014665:Vasodilator Agents / Q000494:pharmacology*; D017557:Ventral Tegmental Area / Q000187:drug effects* / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism; D000097629:Nociceptin
D004298:Dopamine; D018847:Opioid Peptides; D014665:Vasodilator Agents; D005680:gamma-Aminobutyric Acid; D000097629:Nociceptin